Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common
mechanism of adaptive resistance to targeted therapy in cancer. An archetypal example is …

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
Page 1 1 Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine …

Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common
mechanism of adaptive resistance to targeted therapy in cancer,. An archetypal example is …

Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common
mechanism of adaptive resistance to targeted therapy in cancer. An archetypal example is …

Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common
mechanism of adaptive resistance to targeted therapy in cancer. An archetypal example is …

Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common
mechanism of adaptive resistance to targeted therapy in cancer. An archetypal example is …

Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common
mechanism of adaptive resistance to targeted therapy in cancer. An archetypal example is …

Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common
mechanism of adaptive resistance to targeted therapy in cancer. An archetypal example is …

Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common
mechanism of adaptive resistance to targeted therapy in cancer. An archetypal example is …

Results Comparative epigenomic profiles of PRAD and NEPC. We performed ChIP-seq for
the histone post-translational modification H3K27ac to identify active regulatory elements in …